[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-436324-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-436324-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","neoadjuvant-therapy-and-locally-advanced-cancer-diseases-editorial","Neoadjuvant therapy and locally advanced cancer diseases - editorial","","Editorial overview of neoadjuvant therapy (NAT) as a multimodality strategy for locally or far-advanced, initially inoperable cancers, aiming to improve surgical feasibility while balancing risks of surgery-related adverse events and mortality. Reviews NAT variants such as chemotherapy-based regimens, radiotherapy alone or concurrent chemoradiotherapy, and combined/sequential protocols including immunotherapy and targeted therapy. Highlights a Taiwan single-center study comparing short-course RT plus consolidation CT versus conventional long-course CCRT, discussing survival trends and potential prognostic confounders.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/neoadjuvant-therapy-and-locally-advanced-cancer-diseases-editorial/436324/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/neoadjuvant-therapy-and-locally-advanced-cancer-diseases-editorial/436324.png","ImageObject",300,407,{"name":42,"@type":43},"Margaret","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-29",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is neoadjuvant therapy used for locally or far-advanced cancers?","Question",{"text":63,"@type":64},"NAT is used to reverse inoperable clinical situations and improve suitability for surgery. Primary surgery often has low success probability and higher risk of surgery-related adverse events or mortality.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What NAT treatment approaches are discussed in the editorial?",{"text":68,"@type":64},"The editorial discusses NAT by chemotherapy (NACT), radiotherapy alone (NART) or combined with chemotherapy (concurrent chemoradiotherapy), and sequential or combined protocols such as NART+CCT. It also mentions adding agents like immunotherapy and targeted therapy.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the reported findings comparing SCRT+CCT with conventional long-course CCRT?",{"text":72,"@type":64},"Patients receiving SCRT+CCT showed a higher 3-year disease-free survival (81.8% vs 62.1%). The survival advantage was not mirrored by cancer-specific survival or overall survival, and potential discrepancies were linked to selection bias and confounding factors.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},436324,1790792787,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":30,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":111,"preview_page_count":4},137451207643,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","J Chin MedAssoc  \nEDITORIAL  \nNeoadjuvant therapy and locally advanced cancer diseases  \nPeng-Hui Wanga,b,c,*, Szu-Ting Yanga,b  \naDepartment of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC; bInstitute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC; cFemale Cancer Foundation, Taipei, Taiwan, ROC  \nNeoadjuvant therapy (NAT) has become one of the very interesting approaches and also served a potential management in many kinds of cancers, particularly for those patients with locally or far-advanced cancers who need reversing their inoperatable clinical situations to suitability for surgery because these patients are not only at the lowest chance to be managed successfully by primary surgery but also at highest risk tobe complicated by the surgery-related adverse events or even surgery-related mortality.1–4 To enhance the feasibility of subsequent surgical approach, there are many strategies available in the modern cancer treatment (called NAT by multimodality approach), including NAT by chemotherapy (CT) (NACT),1–4 and NAT by radiotherapy (RT) without (NART) or with simultaneous administration of CT (concurrent chemoradiotherapy: NACCRT or combination of CT and RT: NART+NACT),4–6 and all of them can be used alone or furthermore in combination of many potential therapeutic approaches or adding active agents, regardless of their availability in the market or under investigation, including immunotherapy (IO), targeted therapy, and many others.6–10 Moreover, besides aforementioned strategies, many modified protocols, such as sequential application of any one of aforementioned therapeutic approaches, such as NART+following consolidation CT (NART+CCT) have got very impressive and exciting results, according to the reports from many clinical observative studies and prospective randomized clinical trials (RCTs) .6,11–14 The current article entitled“Short-term outcomes of short- and long-course chemoradiotherapy before total mesorectal excision for locally advanced rectal tumors: A single-center study in Taiwan utilizing propensity score matching” may be one of the best examples.14  \nDr. Chang and his colleagues attempted to compare the shortterm outcomes of patients with locally advanced rectal cancers (LARC) treated either with short-course RT+following at least four courses of CCT (SCRT+CCT) or with conventional longcourse CCRT.14 To minimize the risk of selection biases, the authors did their efforts to make the study population appearing more homogeneously, including exclusion of SCRT without following CCT and SCRT+following immediate total mesorectal  \n*Address correspondence. Dr. Peng-Hui Wang, Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, 201, Section 2, Shi-Pai Road, Taipei 112, Taiwan, [ROC. E-mail: phwang@vghtpe.gov.tw](ROC. E-mail: phwang@vghtpe.gov.tw); pongpongwang@ [gmail.com](gmail.com) (P.-H. Wang)  \nConflicts of interest: Dr. Peng-Hui Wang, an editorial board member at the Journal of the Chinese Medical Association, had no role in the peer review process of or decision to publish this article. The other author declares no conflicts of interest related to the subject matter or materials discussed in this article.  \nJournal of Chinese Medical Association. (2024) 87: 969-971.  \nReceived August 15, 2024; accepted August 16, 2024. doi: 10. 1097/JCMA.0000000000001157  \nCopyright © 2024, the Chinese Medical Association. This is an open access article under the CC BY-NC-ND license ([http://creativecommons.org/licenses/](http://creativecommons.org/licenses/)[ ](http://creativecommons.org/licenses/)[by-nc-nd/4.0/](by-nc-nd/4.0/))  \nexcision, or CCRT after December 2019.14 The results showed patients in the SCRT+CCT group had a statistically significantly higher 3-year disease-free survival (DFS) rate than in the CCRT group (81.8% vs 62.1%), although the above-mentioned survival benefit cannot be reproducible by both 3-year cancers","cbCaipUI9Rqvmjjc","https://ap.wps.com/l/cbCaipUI9Rqvmjjc","pdf",277002,"English","# Neoadjuvant therapy as a management strategy\n## NAT modalities and multimodality combinations\n## Short-course vs long-course chemoradiotherapy outcomes\n## Prognostic factors and study interpretation","[{\"question\":\"Why is neoadjuvant therapy used for locally or far-advanced cancers?\",\"answer\":\"NAT is used to reverse inoperable clinical situations and improve suitability for surgery. Primary surgery often has low success probability and higher risk of surgery-related adverse events or mortality.\"},{\"question\":\"What NAT treatment approaches are discussed in the editorial?\",\"answer\":\"The editorial discusses NAT by chemotherapy (NACT), radiotherapy alone (NART) or combined with chemotherapy (concurrent chemoradiotherapy), and sequential or combined protocols such as NART+CCT. It also mentions adding agents like immunotherapy and targeted therapy.\"},{\"question\":\"What were the reported findings comparing SCRT+CCT with conventional long-course CCRT?\",\"answer\":\"Patients receiving SCRT+CCT showed a higher 3-year disease-free survival (81.8% vs 62.1%). The survival advantage was not mirrored by cancer-specific survival or overall survival, and potential discrepancies were linked to selection bias and confounding factors.\"}]","Neoadjuvant therapy and locally advanced cancer diseases - editorial | PDF",1790677610]